Laurion Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Laurion Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-350,766	Closed	-$15.7M	–	358
2024 Q2	$15.7M	Sell	350,766 -279,416	-44%	-$12.9M	0.19%	86
2024 Q1	$29.5M	Buy	630,182 +61,200	+11%	+$2.39M	0.25%	86
2023 Q4	$20.2M	Buy	568,982 +222,345	+64%	+$6.82M	0.17%	115
2023 Q3	$10.3M	Buy	+346,637	New	+$7.14M	0.06%	208
2022 Q2	–	Sell	-79,952	Closed	-$1.75M	–	518
2022 Q1	$1.75M	Buy	+79,952	New	+$1.62M	0.02%	221
2018 Q4	–	Sell	-117,700	Closed	-$3.37M	–	1158
2018 Q3	$3.37M	Buy	+117,700	New	+$3.49M	0.03%	443

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Laurion Capital Management's CRNX Position: Q3 2024 in Review

Laurion Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 350,766 shares — an estimated $15.7M sold.

Laurion Capital Management first reported a position in CRNX in Q3 2018 and held it in 6 quarters. The position peaked at $29.5M in Q1 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

Laurion Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 350,766 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $15.7M.
Laurion Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Laurion Capital Management's Crinetics Pharmaceuticals position peaked at $29.5M in Q1 2024.
235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.